NIH's All of Us Program Reaches a Historic Milestone for Precision Medicine
The National Institutes of Health (NIH) recently announced on June 30, 2026 a landmark achievement: Its All of Us Research Program is now the world's largest integrated genomics and health database. [1] All of Us includes health and genomic data from more than 747,000 participants, including over 535,000 whole genome sequences linked to electronic health records. This gives researchers access to an unprecedented resource for advancing precision medicine and drug development.
747,000+
participants contributing health and genomic data
535,000+
whole genome sequences linked to electronic health records
Why This Matters for Rare Diseases
This is a remarkable milestone for the rare disease community. Since rare diseases affect a small number of individuals, it is difficult for researchers to develop targeted therapies with little genomic data available and small sample sizes. The All of Us program provides a solution by providing a large, diverse dataset that allows scientists to compare genetic information across hundreds of thousands of individuals. Historically, genomic research has disproportionately represented individuals of European ancestry, limiting the ability of precision medicine to benefit everyone equally. By recruiting participants from populations that have been underrepresented in biomedical research, the All of Us program has created a more inclusive dataset that can improve diagnoses and treatment options across ethnic and racial communities.
A More Inclusive Genomic Dataset
For individuals living with rare genetic conditions, larger genomic databases can accelerate the discovery of novel disease genes, improve interpretation of variants of uncertain significance (VUS), and identify patients who may be eligible for clinical trials or emerging therapies. Additionally, the integration of genomic information with electronic health records has enabled researchers to better understand how genetic changes influence disease progression, treatment response, and long-term outcomes.
Recognizing Participant Contributions
Rare Genomics Institute (RG) wants to recognize every individual who has chosen to contribute their health information to the All of Us program. This is a resource that benefits future generations of patients and families. As the database continues to grow toward its goal of enrolling one million or more participants, its value for scientific discovery will continue to increase.
Built on Participant Trust
At RG, we believe that meaningful progress begins with collaboration—between patients, families, clinicians, researchers, and advocates. Josh Denny, CEO of the All of Us Research Program, wrote that more than 747,000 people entrusted the program with their DNA, medical records, and health information, calling the release a milestone built on participant trust rather than simply a technological achievement. This demonstrates what is possible when individuals come together to advance science.
More than 747,000 people entrusted the program with their DNA, medical records, and health information, calling the release a milestone built on participant trust rather than simply a technological achievement.
Looking Ahead
The database does not provide instant answers to the rare disease community’s pressing questions. Instead, its value lies in supporting the initiation of thousands of future studies focused on identifying novel disease mechanisms, validating existing study findings, and ultimately translating discoveries into new diagnostic testing and drug development. The program could shorten the "diagnostic odyssey" for thousands of patients and make precision medicine more equitable. RG is enthusiastic for the future of the All of Us program and will stay committed to following its course through medicine as it supports the rare disease community.
[1] https://www.nih.gov/news-events/news-releases/nihs-all-us-research-program-now-largest-integrated-genomics-health-database-world